Development of a Rucaparib response signature that shows in vitro predictive value to the PARP inhibitors, ABT-888 and Olaparib in ovarian cancer cells

Al Rubaish, Sarah

54 - Featured Poster
Development of a Rucaparib response signature that shows in vitro predictive value to the PARP inhibitors, ABT-888 and Olaparib in ovarian cancer cells

Sunday, March 23, 2014: 7:11 AM

Room 13-16 (Tampa Convention Center)

S. S. Al Rubaish¹, Y. Xiong¹, D. Marchion¹, F. Abbasi¹, S. H. Bush², I. Ramirez², N. Bou Zgheib², P. L. Judson Lancaster¹, R. M. Wenham¹ and J. M. Lancaster¹
¹H. Lee Moffitt Cancer Center, Tampa, FL, ²University of South Florida College of Medicine, Tampa, FL

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

54 - Featured Poster
Development of a Rucaparib response signature that shows in vitro predictive value to the PARP inhibitors, ABT-888 and Olaparib in ovarian cancer cells

54 - Featured Poster Development of a Rucaparib response signature that shows in vitro predictive value to the PARP inhibitors, ABT-888 and Olaparib in ovarian cancer cells

54 - Featured Poster
Development of a Rucaparib response signature that shows in vitro predictive value to the PARP inhibitors, ABT-888 and Olaparib in ovarian cancer cells